Moreover, the N-cadherin antagonist ADH-1 promotes the antitumor response of tumor infiltrating lymphocytes (TILs), interfering with the JAK/STAT pathway [14]: CXCL11 and IRF1 were upregulated after using ADH-1. Here, IRF1 is linked to neoplasm.